trial · primary record
Total Neo-adjuvant Therapy
Rectal Cancer
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 40 |
| Primary completion | 2031-12 |
| Primary endpoint | The primary endpoint of the study is pathological response (pCR) prediction with PET/MRI. |
| Registry ID | NCT06057831 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T13:44:30.870Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06057831
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.